Effects of 5-HTR2A, DRD2,and COMT Genes Polymorphisms and Drug Plasma Concentration on Antipsychotic Response to Olanzapine in Treatment of Early-onset Schizophrenia
Phase of Trial: Phase IV
Latest Information Update: 07 Dec 2016
At a glance
- Drugs Olanzapine (Primary)
- Indications Schizophrenia
- Focus Pharmacodynamics; Pharmacokinetics
- 10 Jun 2017 Biomarkers information updated
- 30 Nov 2016 Planned number of patients changed from 100 to 150.
- 26 Feb 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.